The patent for rimegepant, a medication used to treat migraines, is set to expire on December 20, 2024 [1]. This expiration date pertains to U.S. Patent No. 10,821,192 [1].
When can generic versions of rimegepant be sold?
Following the expiration of its primary patent, generic versions of rimegepant could potentially become available. The actual market entry of generics often depends on various factors, including any additional patents that may be in place and potential litigation [2]. DrugPatentWatch.com tracks these patent expirations and potential market entry dates for pharmaceuticals [1, 2].
Are there other patents protecting rimegepant?
While U.S. Patent No. 10,821,192 has a listed expiration of December 20, 2024, pharmaceutical companies often hold multiple patents covering different aspects of a drug, such as its formulation, method of use, or manufacturing process [2]. These additional patents can extend market exclusivity even after a primary patent expires [2]. Information on the full patent landscape for rimegepant can be found on sites like DrugPatentWatch.com [1, 2].
What happens when a drug patent expires?
When a patent for a brand-name drug expires, it typically opens the door for generic manufacturers to produce and sell lower-cost versions of the medication. This process can significantly increase competition and lead to reduced prices for consumers [2].
How is rimegepant used for migraines?
Rimegepant is an oral medication approved for the acute treatment of migraine with or without aura in adults [3]. It belongs to a class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists [3].
What is the status of rimegepant exclusivity?
The U.S. Patent No. 10,821,192 for rimegepant has a scheduled expiration on December 20, 2024 [1]. It is important to note that patent information can be complex, and other patents or exclusivity periods may affect the actual market availability of generic versions [2].
Sources:
1. DrugPatentWatch.com. (n.d.). Rimegepant Patent Expiration. Retrieved from https://drugpatentwatch.com/
2. DrugPatentWatch.com. (n.d.). Understanding Drug Patents and Exclusivity. Retrieved from https://drugpatentwatch.com/
3. U.S. Food & Drug Administration. (n.d.). Drug Approval Package: Ubrelvy. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety/drug-approval-packages